RenovoRx Presents Positive Interim Phase III Data in Pancreatic Cancer

Logo - Bio Tuesdays

RenovoRx (NASDAQ:RNXT) presented new positive data on progression-free survival from the pivotal Phase 3 open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer.

The interim data was featured as a late-breaking oral presentation at the 2023 ESMO World Congress on Gastrointestinal Cancer, and presented by Michael Pishvaian, M.D., Ph.D., Johns Hopkins Medicine and principal Investigator of the TIGeR-PaC study.

View the entire article on Bio Tuesdays

Previous Post
RenovoRx, Imugene Partner to Deliver Oncolytic Virus Therapy
Next Post
Intra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer